Daniel E Cohen - JoVE Visualize

Showing results (11-20 of 50) with videos related to

Pageof 5

Sort By:

Pharmacology Research & Perspectives|November 23, 2022

Effects of a ritonavir-containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjectsJiuhong Zha, Qi Jiang, Betty B Yao, et al.

Infectious Diseases and Therapy|September 24, 2017

Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical TrialsDarshan A Mehta, Eric Cohen, Mariem Charafeddine, et al.

Journal of Virological Methods|December 23, 2014

Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapyChristoph Sarrazin, Heiner Wedemeyer, Gavin Cloherty, et al.

Behavior Research Methods|August 1, 2025

Modeling memories, predicting prospections: Automated scoring of autobiographical detail narration using large language modelsJonas Klus, Daniel E Cohen, Alexis N Garcia, et al.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 1, 2024

Sleep-wake behavior, perceived fatigability, and cognitive reserve in older adultsNancy Kerner, Terry E Goldberg, Hannah R Cohen, et al.

European Journal of Clinical Pharmacology|October 7, 2018

Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trialsDiana L Shuster, Rajeev M Menon, Bifeng Ding, et al.

Plos One|June 1, 2018

Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimensAparna Vasanthakumar, Justin W Davis, Manal Abunimeh, et al.

Cytometry. Part B, Clinical Cytometry|September 20, 2021

Biomarkers for the clinical development of antiviral therapiesTeresa I Ng, Patrick K Dorr, Preethi Krishnan, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2009

Methicillin-resistant Staphylococcus aureus colonization, behavioral risk factors, and skin and soft-tissue infection at an ambulatory clinic serving a large population of HIV-infected men who have sex with menJohn D Szumowski, Kenneth M Wener, Howard S Gold, et al.

Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2009

A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeksJoseph Gathe, Barbara A da Silva, Daniel E Cohen, et al.

Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:

Pageof 5

Pharmacology Research & Perspectives|November 23, 2022

Effects of a ritonavir-containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjectsJiuhong Zha, Qi Jiang, Betty B Yao, et al.

Infectious Diseases and Therapy|September 24, 2017

Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical TrialsDarshan A Mehta, Eric Cohen, Mariem Charafeddine, et al.

Journal of Virological Methods|December 23, 2014

Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapyChristoph Sarrazin, Heiner Wedemeyer, Gavin Cloherty, et al.

Behavior Research Methods|August 1, 2025

Modeling memories, predicting prospections: Automated scoring of autobiographical detail narration using large language modelsJonas Klus, Daniel E Cohen, Alexis N Garcia, et al.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 1, 2024

Sleep-wake behavior, perceived fatigability, and cognitive reserve in older adultsNancy Kerner, Terry E Goldberg, Hannah R Cohen, et al.

European Journal of Clinical Pharmacology|October 7, 2018

Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trialsDiana L Shuster, Rajeev M Menon, Bifeng Ding, et al.

Plos One|June 1, 2018

Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimensAparna Vasanthakumar, Justin W Davis, Manal Abunimeh, et al.

Cytometry. Part B, Clinical Cytometry|September 20, 2021

Biomarkers for the clinical development of antiviral therapiesTeresa I Ng, Patrick K Dorr, Preethi Krishnan, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2009

Methicillin-resistant Staphylococcus aureus colonization, behavioral risk factors, and skin and soft-tissue infection at an ambulatory clinic serving a large population of HIV-infected men who have sex with menJohn D Szumowski, Kenneth M Wener, Howard S Gold, et al.

Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2009

A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeksJoseph Gathe, Barbara A da Silva, Daniel E Cohen, et al.

Pageof 5